ReviewFrontiers in cardiovascular medicine2026
Onco-hypertension: hypertension induced by VEGF pathway inhibition.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Angiogenesis inhibitors and the risk of peripheral artery aneurysm and dissection: a cross-database study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapies are increasingly linked to a wide spectrum of cardiovascular toxicities, presenting significant challenges in the long-term care of oncology patients. Among these, therapy-induced hypertension stands out as one of the most consistent and clinically relevant adverse effects, especially with agents targeting the VEGF pathway. Understanding the mechanisms behind this form of hypertension is critical, as it not only represents a modifiable cardiovascular risk factor but may also serve as a biomarker of therapeutic efficacy in certain cancer treatments. Clinical evidence underscores the importance of early detection and aggressive blood pressure control to improve both cardiovascular and oncologic outcomes. The most well-characterized and clinically significant subtype of therapy-related hypertension is that induced by VEGF pathway inhibitors, owing to its high incidence, rapid onset, and well-defined mechanistic basis. In this review, we specifically examine VEGFi-associated hypertension as a prototypical model of onco-hypertension. Evidence-based strategies for managing therapy-induced hypertension emphasize early detection and individualized treatment plans. Renin-angiotensin system inhibitors (RAAS inhibitors) are frequently recommended as first-line agents due to their favorable cardiovascular profile and potential synergistic effects with some cancer therapies. Calcium-channel blockers (CCBs) also demonstrate strong efficacy and are often used in combination regimens to achieve optimal blood pressure control. Successful management requires a multidisciplinary approach, integrating expertise from oncology, cardiology, and primary care. Proactive surveillance, patient education, and risk stratification are essential components of care. As the field of cardio-oncology continues to evolve, structured blood pressure management remains a cornerstone of safe and effective cancer care, ensuring that patients receive optimal therapeutic benefit while minimizing cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.